Table 2 Continuous abstinence rates and 7-day point prevalence
Varenicline group | Placebo group | OR | 95% CI | p-value | |
|---|---|---|---|---|---|
Continuous abstinence rate | |||||
CAR 4–12 weeks | 40.0% | 20.0% | 2.67 | [1.25–5.68] | 0.011 |
CAR 4–24 weeks | 34.3% | 17.1% | 2.52 | [1.14–5.58] | 0.022 |
7-day point prevalence | |||||
Week-4 | 41.4% | 22.9% | 2.39 | [1.15–4.97] | 0.020 |
Week-5 | 41.4% | 27.1% | 1.86 | [0.93–3.86] | 0.076 |
Week-6 | 40.0% | 25.7% | 1.93 | [0.94–3.95] | 0.073 |
Week-7 | 40.0% | 25.7% | 1.93 | [0.94–3.95] | 0.073 |
Week-8 | 40.0% | 20.0% | 2.67 | [1.25–5.68] | 0.011 |
Week-12 | 40.0% | 20.0% | 2.67 | [1.25–5.68] | 0.011 |
Week-24 | 34.3% | 17.1% | 2.52 | [1.14–5.58] | 0.022 |